atorvastatin has been researched along with Obesity in 67 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 24 (35.82) | 29.6817 |
| 2010's | 31 (46.27) | 24.3611 |
| 2020's | 12 (17.91) | 2.80 |
| Authors | Studies |
|---|---|
| Bao, L; Liao, M; Liu, C; Liu, H; Liu, S; Wang, J; Wang, K; Wang, L; Wang, W; Wang, Y; Zhang, J; Zheng, Z; Zhou, N | 1 |
| Chen, Z; Dai, G; Fan, W; Ma, D; Mo, W; Pan, J; Wu, G; Zhang, X | 1 |
| Banerjee, S; Biswas, S; Chanda, J; Kar, A; Mukherjee, PK; Tiwari, A; Ulrich-Merzenich, G | 1 |
| Brown, JD; Donahoo, WT; Hampp, C; Sarayani, A; Winterstein, AG | 1 |
| Namazova, GA; Shupenina, EY; Vasyuk, YA; Zavyalova, AI | 1 |
| Chatsudthipong, V; Cherngwelling, R; Jaikumkao, K; Lungkaphin, A; Pengrattanachot, N; Pongchaidecha, A; Swe, MT; Thongnak, L | 1 |
| Carvalho, D; Rodrigues, E; Saavedra, A | 1 |
| Devasani, K; Kaul, R; Majumdar, A | 1 |
| Amput, P; Arunsak, B; Chattipakorn, K; Chattipakorn, N; Chattipakorn, SC; Jaiwongkum, T; Kerdphoo, S; Palee, S; Pratchayasakul, W; Thonusin, C; Tosukhowong, T | 1 |
| Amput, P; Arunsak, B; Chattipakorn, N; Chattipakorn, SC; Jaiwongkam, T; Kerdphoo, S; Palee, S; Pratchayasakul, W | 1 |
| Mao, Y; Ning, D; Tang, S; Wang, D; Wang, T; Xiong, T; Yang, X; Zhong, H; Zhu, G | 1 |
| Christiansen, LB; Ciborowski, M; Desler, C; Dohlmann, TL; Kretowski, A; Larsen, S; Ludvigsen, TP; Martinussen, T; Olsen, LH; Orlando, P; Parfieniuk, E; Szczerbinski, L; Tiano, L | 1 |
| Abdel-Gabbar, M; Anwar, S; El-Zanaty, AM; Esmail, M; Kandeil, M | 1 |
| Cheung, LK; Chow, DS; El-Zailik, A; Sherman, V; Wang, Y | 1 |
| Christopher-Stine, L; Isackson, PJ; Kitzmiller, JP; Luzum, JA; Ma, C; Nguyen, LM; Ochs-Balcom, HM; Peltier, W; Tarnopolsky, M; Vladutiu, GD; Weisman, M; Wortmann, RL | 1 |
| Huang, D; Liu, H; Niu, T; Wang, K; Yang, J | 1 |
| Bochar, O; Bondarenko, O; Karpyshyn, N; Maksymets, T; Sklyarov, Y; Sorochka, M | 1 |
| Brudi, P; Hanson, ME; Jimenez, JG; Massaad, R; Pirags, V; Rosen, JB; Triscari, J; Vides, H | 1 |
| Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP | 1 |
| Eleftheriadou, I; Grigoropoulou, P; Katsilambros, N; Makrilakis, K; Margeli, A; Papassotiriou, I; Perrea, D; Tentolouris, N; Zoupas, C | 1 |
| Barrett, PH; Chan, DC; Ng, TW; Ooi, EM; Watts, GF | 1 |
| Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A | 1 |
| Chen, ZY; Gao, LH; Lei, L; Li, CN; Liu, Q; Liu, SN; Shen, ZF; Sun, SJ | 1 |
| Bochar, OM | 1 |
| Adámková, V; Češka, R; Dlouhá, D; Hrubá, P; Hubáček, JA; Viklický, O; Vrablík, M; Zlatohlavek, L | 1 |
| Capel, F; Chabrier, G; Cynober, L; de Bandt, JP; Durand, C; Jouve, C; Le Plenier, S; Moinard, C; Morio, B; Pitois, E; Rigaudière, JP | 1 |
| Hao, Z; Li, G; Liao, H; Liu, Y; Xiao, C; Zheng, D | 1 |
| Barwari, T; Bonora, E; Fernández-Hernando, C; Goedeke, L; Hughes, AD; Kaudewitz, D; Kiechl, S; Mayr, M; Moschen, AR; Ramírez, CM; Rotllan, N; Santer, P; Skroblin, P; Tilg, H; Whitehead, M; Willeit, J; Willeit, P; Yin, X; Zampetaki, A | 1 |
| Bjorndahl, TC; Caplice, NM; Fitzgerald, GF; London, LE; Mandal, R; Murphy, K; Ross, RP; Ryan, PM; Shanahan, F; Stanton, C; Wishart, DS | 1 |
| Byrne, CD; Chipperfield, AJ; Clough, GF; Gamble, J; Krentz, AJ; Turzyniecka, M; Walter, L; Wild, SH | 1 |
| Davy, KP; Dengo, AL; Orr, JS; Rivero, JM | 1 |
| Favaro, RR; Furuya, DT; Machado, UF; Martins, JO; Poletto, AC; Zorn, TM | 1 |
| Huan, Y; Huang, H; Shen, ZF; Song, GM; Sun, SJ; Zhang, N | 1 |
| Acharjee, S; Cannon, CP | 1 |
| Caballero, F; Elena, M; Fernández, A; Fernández-Checa, JC; García-Ruiz, C; Llacuna, L; Martínez, L; Matías, N; Montfort, CV; Morales, A; Rimola, A | 1 |
| Wilke, RA | 1 |
| An, LM; Chang, WT; Chen, IJ; Lin, HL; Shen, KP; Wu, BN | 1 |
| Hassanian, MA; Samy, W | 1 |
| Choi, YJ; Geaney, JC; Karpf, DB; Krauss, RM; Naim, S; Roberts, BK; Wang, X; Wojnoonski, K | 1 |
| Ajamieh, H; Chen, J; Chu, E; Farrell, G; Teoh, N; Wong, HJ; Yu, J | 1 |
| El-Moselhy, MA; Heeba, GH; Mourad, AA; Taye, A | 1 |
| Gracia-Sancho, J | 1 |
| Gerasimidis, T; Kadoglou, NP; Kapelouzou, A; Kostakis, A; Liapis, CD; Moumtzouoglou, A; Sailer, N | 1 |
| Artamoshina, NE; Belaya, OL; Bondar, KY; Kuropteva, ZV; Lazutina, OM; Raider, LM; Yakovleva, TV | 1 |
| Andersson, TB; Asberg, A; Bremer, S; Christensen, H; Hjelmesæth, J; Jakobsen, GS; Molden, E; Sandbu, R; Skottheim, IB; Ulvestad, M | 1 |
| Barrett, PH; Beilin, LJ; Chan, DC; Mori, TA; Redgrave, TG; Watts, GF | 3 |
| Barrett, PH; Chan, DC; Croft, KD; Ji, J; Johnson, AG; Loehrer, F; Serone, AP; Watts, GF | 1 |
| Lawrence, JM; Reckless, JP; Reid, J; Stirling, C; Taylor, GJ | 1 |
| Baykan, M; Eminagaoglu, S; Gökçe, M; Orem, A; Orem, C; Uydu, HA; Yilmaz, R | 1 |
| Blanco, S; Egido, J; Gómez-Guerrero, C; López, D; Romero, R; Vaquero, M | 1 |
| Moreno Sánchez, D | 1 |
| Athyros, VG; Didangelos, TP; Elisaf, M; Kakafika, AI; Karagiannis, A; Kleta, D; Mikhailidis, DP; Papageorgiou, AA; Peletidou, A; Tziomalos, K | 1 |
| Ishibashi, S; Kusaka, I; Matsuoka, H; Nagasaka, S; Nakata, M; Yada, T | 1 |
| Hazen, SL; Nicholls, SJ; Nissen, SE; Ntanios, F; Schoenhagen, P; Sipahi, I; Tuzcu, EM; Wun, CC | 1 |
| Barrett, PH; Chan, DC; Nguyen, MN; Watts, GF | 1 |
| Ciccarelli, L; Corradi, L; Derosa, G; Fogari, E; Fogari, R; Lazzari, P; Preti, P; Zoppi, A | 1 |
| Nesto, RW; Singh, PP | 1 |
| Kulbertus, H | 1 |
| Das, S; Gidding, SS; Mitchell, D; Zhang, S | 1 |
| Barrett, PH; Chan, DC; Hegele, RA; van Bockxmeer, FM; Wang, J; Watts, GF | 1 |
| De Angelis, S; De Lorenzo, A; Di Daniele, N; Di Renzo, L; Miani, N; Noce, A; Tozzo, C | 1 |
| Goldstein, MR; Mascitelli, L; Pezzetta, F | 1 |
| Mertens, A; Muls, E; Vansant, G | 1 |
| Barrett, PH; Chan, DC; James, AP; Mamo, JC; Martins, IJ; Mori, TA; Redgrave, TG; Watts, GF | 1 |
| Barrett, PH; Beilin, LJ; Chan, DC; Mori, TA; Watts, GF | 1 |
3 review(s) available for atorvastatin and Obesity
| Article | Year |
|---|---|
Office-based global cardiometabolic risk assessment: a simple tool incorporating nontraditional markers.
Topics: Atorvastatin; Biomarkers; Cardiovascular Diseases; Clinical Trials as Topic; Female; Heptanoic Acids; Humans; Hypercholesterolemia; Hypertension; Male; Obesity; Office Visits; Practice Patterns, Physicians'; Pravastatin; Pyrroles; Risk Assessment; Smoking; United States | 2010 |
High-density lipoprotein (HDL) cholesterol: leveraging practice-based biobank cohorts to characterize clinical and genetic predictors of treatment outcome.
Topics: Apolipoprotein A-I; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Databases, Nucleic Acid; Dose-Response Relationship, Drug; Dyslipidemias; Electronic Health Records; Genetic Association Studies; Genetic Markers; Heptanoic Acids; Humans; Obesity; Pravastatin; Pyrroles; Risk Assessment; Simvastatin; Treatment Outcome | 2011 |
[Medical management of primary nonalcoholic fatty liver disease].
Topics: Anti-Obesity Agents; Anticholesteremic Agents; Atorvastatin; Chromans; Diabetes Mellitus, Type 2; Fatty Liver; Heptanoic Acids; Humans; Hypoglycemic Agents; Insulin Resistance; Lactones; Metabolic Syndrome; Metformin; Obesity; Orlistat; Prevalence; Pyrroles; Rosiglitazone; Thiazolidinediones; Troglitazone | 2005 |
21 trial(s) available for atorvastatin and Obesity
| Article | Year |
|---|---|
Consistency of effect of ezetimibe/simvastatin compared with intensified lipid-lowering treatment strategies in obese and non-obese diabetic subjects.
Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Apolipoproteins B; Atorvastatin; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Ezetimibe; Female; Fluorobenzenes; Heptanoic Acids; Humans; Male; Middle Aged; Obesity; Peptide Fragments; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Simvastatin; Sulfonamides; Treatment Outcome; Young Adult | 2013 |
Effect of atorvastatin on baroreflex sensitivity in subjects with type 2 diabetes and dyslipidaemia.
Topics: Aged; Atorvastatin; Baroreflex; Body Mass Index; Cardiovascular Agents; Cardiovascular Diseases; Combined Modality Therapy; Diabetes Mellitus, Type 2; Diabetic Angiopathies; Diabetic Cardiomyopathies; Diet, Fat-Restricted; Dyslipidemias; Female; Greece; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Myalgia; Obesity; Patient Dropouts; Prospective Studies; Pyrroles; Risk Factors | 2014 |
Atorvastatin plus omega-3 fatty acid ethyl ester decreases very-low-density lipoprotein triglyceride production in insulin resistant obese men.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Atorvastatin; Docosahexaenoic Acids; Drug Combinations; Drug Therapy, Combination; Dyslipidemias; Eicosapentaenoic Acid; Heptanoic Acids; Humans; Insulin Resistance; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Treatment Outcome; Triglycerides | 2014 |
Combined effect of appointment telmisartan and atorvastatin on hemodynamic indicators and the indicators of lipid profile in patients with arterial hypertension combined with obesity and steatohepatitis.
Topics: Acetamides; Adipokines; Anticholesteremic Agents; Antihypertensive Agents; Atorvastatin; Benzimidazoles; Benzoates; Breath Tests; Cholesterol, LDL; Drug Therapy, Combination; Fatty Liver; Female; Hemodynamics; Heptanoic Acids; Humans; Hypertension; Lipids; Male; Middle Aged; Obesity; Pyrroles; Telmisartan; Triglycerides | 2014 |
Muscle microvascular dysfunction in central obesity is related to muscle insulin insensitivity but is not reversed by high-dose statin treatment.
Topics: Adolescent; Adult; Aged; Atorvastatin; Biological Transport; Blood Pressure; Double-Blind Method; Energy Metabolism; Exercise Test; Female; Glucose; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Lipids; Male; Microcirculation; Middle Aged; Muscle, Skeletal; Obesity; Pyrroles | 2009 |
Arterial destiffening with atorvastatin in overweight and obese middle-aged and older adults.
Topics: Adult; Aged; Aging; Atorvastatin; Blood Flow Velocity; C-Reactive Protein; Cardiovascular Diseases; Carotid Arteries; Cholesterol, LDL; Double-Blind Method; Elasticity; Female; Femoral Artery; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Obesity; Overweight; Pyrroles; Regional Blood Flow; Risk Factors | 2009 |
Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Aryldialkylphosphatase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Cross-Sectional Studies; Disease Progression; Fatty Liver; Female; Glutathione Peroxidase; Hepatitis; Heptanoic Acids; Humans; Lipid Peroxidation; Lipoproteins, HDL; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pyrroles; Risk Factors; Triglycerides | 2011 |
Effects of the PPAR-δ agonist MBX-8025 on atherogenic dyslipidemia.
Topics: Acetates; Analysis of Variance; Atherosclerosis; Atorvastatin; Biomarkers; Chi-Square Distribution; Double-Blind Method; Drug Therapy, Combination; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypolipidemic Agents; Lipoproteins; Male; Middle Aged; Obesity; Overweight; Particle Size; PPAR gamma; Pyrroles; Time Factors; Treatment Outcome; Triazoles | 2012 |
Regulatory effects of HMG CoA reductase inhibitor and fish oils on apolipoprotein B-100 kinetics in insulin-resistant obese male subjects with dyslipidemia.
Topics: Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Blood Pressure; Body Mass Index; Body Weight; Fasting; Fatty Acids, Nonesterified; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Insulin; Insulin Resistance; Kinetics; Male; Middle Aged; Obesity; Placebos; Pyrroles | 2002 |
Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.
Topics: Adult; Apolipoprotein A-I; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over Studies; Diet; Double-Blind Method; Fenofibrate; Heptanoic Acids; Humans; Hypolipidemic Agents; Insulin; Kinetics; Lipoproteins; Lipoproteins, HDL; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Metabolic Syndrome; Middle Aged; Obesity; Placebos; Pyrroles; Triglycerides | 2003 |
The effect of high dose atorvastatin therapy on lipids and lipoprotein subfractions in overweight patients with type 2 diabetes.
Topics: Aged; Aged, 80 and over; Analysis of Variance; Apolipoproteins B; Atorvastatin; Body Mass Index; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Female; Follow-Up Studies; Heptanoic Acids; Humans; Lipid Metabolism; Lipoproteins; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Reference Values; Treatment Outcome | 2004 |
Targeting vascular risk in patients with metabolic syndrome but without diabetes.
Topics: Aged; Anticholesteremic Agents; Atorvastatin; C-Reactive Protein; Diabetes Mellitus; Drug Therapy, Combination; Female; Fenofibrate; Heptanoic Acids; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Metabolic Syndrome; Middle Aged; Obesity; Prevalence; Prospective Studies; Pyrroles; Risk Factors; Risk Reduction Behavior | 2005 |
Effects of obesity on lipid-lowering, anti-inflammatory, and antiatherosclerotic benefits of atorvastatin or pravastatin in patients with coronary artery disease (from the REVERSAL Study).
Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Biomarkers; Body Mass Index; C-Reactive Protein; Coronary Disease; Coronary Vessels; Disease Progression; Endosonography; Female; Heptanoic Acids; Humans; Inflammation; Lipids; Male; Middle Aged; Obesity; Pravastatin; Pyrroles; Risk Factors | 2006 |
Factorial study of the effect of n-3 fatty acid supplementation and atorvastatin on the kinetics of HDL apolipoproteins A-I and A-II in men with abdominal obesity.
Topics: Abdominal Fat; Anticholesteremic Agents; Apolipoprotein A-I; Apolipoprotein A-II; Atorvastatin; Dietary Supplements; Double-Blind Method; Drug Therapy, Combination; Fatty Acids, Omega-3; Fish Oils; Gas Chromatography-Mass Spectrometry; Heptanoic Acids; Humans; Hyperlipidemias; Insulin Resistance; Kinetics; Lipoproteins, HDL; Male; Middle Aged; Obesity; Placebos; Pyrroles; Treatment Outcome | 2006 |
Effects of amlodipine-atorvastatin combination on inflammation markers and insulin sensitivity in normocholesterolemic obese hypertensive patients.
Topics: Adult; Aged; Amlodipine; Atorvastatin; Biomarkers; Blood Glucose; Body Mass Index; Calcium Channel Blockers; Cholesterol; Cross-Over Studies; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Inflammation; Insulin Resistance; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tablets; Tumor Necrosis Factor-alpha | 2006 |
Variation in Niemann-Pick C1-like 1 gene as a determinant of apolipoprotein B-100 kinetics and response to statin therapy in centrally obese men.
Topics: Adult; Anti-Obesity Agents; Apolipoprotein B-100; Atorvastatin; Cholesterol, VLDL; Drug Resistance; Genetic Variation; Genotype; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Male; Membrane Proteins; Membrane Transport Proteins; Middle Aged; Obesity; Pyrroles; Treatment Outcome | 2008 |
The effect of atorvastatin on postprandial lipaemia in overweight or obese women homozygous for apo E3.
Topics: Adult; Apolipoprotein E3; Apolipoproteins E; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol; Cholesterol, HDL; Double-Blind Method; Energy Intake; Female; Heptanoic Acids; Homozygote; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Middle Aged; Obesity; Polymerase Chain Reaction; Postprandial Period; Pyrroles; Triglycerides | 2001 |
Effect of atorvastatin on chylomicron remnant metabolism in visceral obesity: a study employing a new stable isotope breath test.
Topics: Anticholesteremic Agents; Atorvastatin; Body Mass Index; Breath Tests; Carbon Dioxide; Carbon Isotopes; Cholesterol; Chylomicron Remnants; Chylomicrons; Double-Blind Method; Heptanoic Acids; Humans; Hyperlipidemias; Lipoproteins; Obesity; Placebos; Pyrroles; Time Factors; Triglycerides; Viscera | 2002 |
Mechanism of action of a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor on apolipoprotein B-100 kinetics in visceral obesity.
Topics: Anticholesteremic Agents; Apolipoprotein B-100; Apolipoproteins B; Atorvastatin; Double-Blind Method; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Kinetics; Lipoproteins; Lipoproteins, IDL; Lipoproteins, LDL; Lipoproteins, VLDL; Male; Middle Aged; Obesity; Pyrroles; Viscera | 2002 |
Effect of atorvastatin and fish oil on plasma high-sensitivity C-reactive protein concentrations in individuals with visceral obesity.
Topics: Anticholesteremic Agents; Atorvastatin; Biomarkers; C-Reactive Protein; Colorimetry; Cross-Sectional Studies; Enzyme Inhibitors; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl CoA Reductases; Immunoassay; Interleukin-6; Male; Middle Aged; Obesity; Pyrroles; Tumor Necrosis Factor-alpha | 2002 |
Factorial study of the effects of atorvastatin and fish oil on dyslipidaemia in visceral obesity.
Topics: Atorvastatin; Diet; Double-Blind Method; Drug Synergism; Exercise; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipids; Lipoproteins; Male; Middle Aged; Obesity; Placebos; Pyrroles; Risk Factors | 2002 |
43 other study(ies) available for atorvastatin and Obesity
| Article | Year |
|---|---|
Structural Modification of Natural Product Ganomycin I Leading to Discovery of a α-Glucosidase and HMG-CoA Reductase Dual Inhibitor Improving Obesity and Metabolic Dysfunction in Vivo.
Topics: alpha-Glucosidases; Animals; Anti-Obesity Agents; Drug Stability; Fatty Liver; Female; Gastrointestinal Microbiome; Glycoside Hydrolase Inhibitors; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactones; Male; Metabolic Syndrome; Mice, Inbred C57BL; Microsomes, Liver; Obesity; Rats, Sprague-Dawley; Swine; Terpenes | 2018 |
N6-Methyladenosine Demethylase FTO (Fat Mass and Obesity-Associated Protein) as a Novel Mediator of Statin Effects in Human Endothelial Cells.
Topics: Adenosine; Alpha-Ketoglutarate-Dependent Dioxygenase FTO; Atorvastatin; Endothelial Cells; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intercellular Adhesion Molecule-1; Obesity; RNA, Messenger; Vascular Cell Adhesion Molecule-1 | 2022 |
Combining LC-MS/MS profiles with network pharmacology to predict molecular mechanisms of the hyperlipidemic activity of Lagenaria siceraria stand.
Topics: Animals; Atorvastatin; Chromatography, Liquid; Cucurbita; Flavonoids; Glycosides; Hesperidin; Hyperlipidemias; Hypertension; Insulins; Network Pharmacology; Obesity; Plant Extracts; Proto-Oncogene Proteins c-akt; Rats; Tandem Mass Spectrometry | 2023 |
Topiramate Utilization After Phentermine/Topiramate Approval for Obesity Management: Risk Minimization in the Era of Drug Repurposing.
Topics: Anti-Obesity Agents; Atorvastatin; Drug Approval; Drug Repositioning; Female; Fructose; Humans; Male; Metformin; Obesity; Phentermine; Pregnancy; Topiramate | 2022 |
[Can a lipophilic statin improve the treatment of heart failure with preserved ejection fraction in patients with hypertension and obesity?]
Topics: Atorvastatin; Diabetes Mellitus, Type 2; Female; Heart Failure; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Obesity; Stroke Volume; Ventricular Dysfunction, Left; Ventricular Function, Left | 2023 |
Atorvastatin attenuates obese-induced kidney injury and impaired renal organic anion transporter 3 function through inhibition of oxidative stress and inflammation.
Topics: Acute Kidney Injury; Animals; Antioxidants; Atorvastatin; Diet, High-Fat; Humans; Inflammation; Insulin; Insulin Resistance; Kidney; Lipid Metabolism; Obesity; Organic Anion Transporters, Sodium-Independent; Oxidative Stress; Rats; Rats, Wistar | 2020 |
[Dyslipidemia Secondary to Hypothyroidism and Cholestasis].
Topics: Atorvastatin; Autoimmune Diseases; Cholestasis; Diabetes Mellitus; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypothyroidism; Liver Cirrhosis, Biliary; Middle Aged; Obesity; Thyroxine; Withholding Treatment | 2020 |
Supplementation of pyrroloquinoline quinone with atorvastatin augments mitochondrial biogenesis and attenuates low grade inflammation in obese rats.
Topics: Animals; Anti-Inflammatory Agents; Atorvastatin; Blood Glucose; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Inflammation Mediators; Lipids; Liver; Male; Mitochondria, Liver; Obesity; Organelle Biogenesis; PQQ Cofactor; Rats, Sprague-Dawley | 2020 |
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor exerts greater efficacy than atorvastatin on improvement of brain function and cognition in obese rats.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Brain; Cognition; Diet, High-Fat; Enzyme Inhibitors; Female; Obesity; Oxidative Stress; PCSK9 Inhibitors; Proprotein Convertase 9; Rats | 2020 |
PCSK9 inhibitor effectively attenuates cardiometabolic impairment in obese-insulin resistant rats.
Topics: Animals; Apoptosis; Atorvastatin; Calcium Signaling; Diet, High-Fat; Disease Models, Animal; Female; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin Resistance; Metabolic Syndrome; Mitochondria, Heart; Myocytes, Cardiac; Obesity; PCSK9 Inhibitors; Proprotein Convertase 9; Rats, Wistar; Recovery of Function; Serine Proteinase Inhibitors; Ventricular Function, Left | 2020 |
Long-term atorvastatin or the combination of atorvastatin and nicotinamide ameliorate insulin resistance and left ventricular diastolic dysfunction in a murine model of obesity.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Blood Glucose; Diet, High-Fat; Drug Therapy, Combination; Insulin; Insulin Resistance; Male; Mice; Mice, Inbred C57BL; Niacinamide; Obesity; Random Allocation; Ventricular Dysfunction, Left; Vitamin B Complex | 2020 |
Atorvastatin impairs liver mitochondrial function in obese Göttingen Minipigs but heart and skeletal muscle are not affected.
Topics: Animals; Atorvastatin; Biomarkers; Cell Respiration; Citrate (si)-Synthase; Hydrogen Peroxide; Male; Metabolome; Mitochondria, Heart; Mitochondria, Liver; Mitochondria, Muscle; Obesity; Oxidation-Reduction; Oxidative Stress; Protein Carbonylation; Swine; Swine, Miniature; Ubiquinone | 2021 |
Effect of Nigella sativa, atorvastatin, or L-Carnitine on high fat diet-induced obesity in adult male Albino rats.
Topics: Animals; Anti-Obesity Agents; Atherosclerosis; Atorvastatin; Blood Glucose; Body Weight; Carnitine; Diet, High-Fat; Fatty Liver; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Nigella sativa; Obesity; Plant Extracts; Rats; Rats, Wistar | 2021 |
Simultaneous LC-MS/MS analysis of simvastatin, atorvastatin, rosuvastatin and their active metabolites for plasma samples of obese patients underwent gastric bypass surgery.
Topics: Adult; Atherosclerosis; Atorvastatin; Calibration; Chromatography, High Pressure Liquid; Female; Gastric Bypass; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Obesity; Postoperative Period; Preoperative Period; Reproducibility of Results; Rosuvastatin Calcium; Simvastatin; Tandem Mass Spectrometry | 2019 |
Clinical features related to statin-associated muscle symptoms.
Topics: Aged; Atorvastatin; Female; Heart Diseases; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Logistic Models; Lovastatin; Male; Medical History Taking; Middle Aged; Muscle Weakness; Muscular Diseases; Myalgia; Obesity; Odds Ratio; Pravastatin; Retrospective Studies; Rhabdomyolysis; Risk Factors; Rosuvastatin Calcium; Simvastatin; Smoking; White People | 2019 |
Moderate- and Low-Dose of Atorvastatin Alleviate Cognition Impairment Induced by High-Fat Diet via Sirt1 Activation.
Topics: Animals; Antioxidants; Atorvastatin; Body Weight; Cognition; Cognitive Dysfunction; Diet, High-Fat; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Male; Mice, Inbred C57BL; Obesity; Oxidative Stress; Sirtuin 1 | 2019 |
Comparison of metabolic profile of obese non-diabetic patients with coronary artery disease depending on atorvastatin dose.
Topics: Atorvastatin; Coronary Artery Disease; Diabetes Mellitus, Type 2; Female; Humans; Male; Metabolome; Obesity; Ukraine | 2019 |
Are statins 'IDEAL' for non-alcoholic fatty liver disease?
Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides | 2014 |
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones | 2014 |
Atorvastatin helps preserve pancreatic β cell function in obese C57BL/6 J mice and the effect is related to increased pancreas proliferation and amelioration of endoplasmic-reticulum stress.
Topics: Animals; Apoptosis; Atorvastatin; Blotting, Western; Cell Survival; Endoplasmic Reticulum Stress; Fluorescent Antibody Technique; Heptanoic Acids; Insulin-Secreting Cells; Male; Mice; Mice, Inbred C57BL; Obesity; Pancreas; Pyrroles; Real-Time Polymerase Chain Reaction | 2014 |
SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population.
Topics: Aged; Atorvastatin; Czech Republic; Diabetes Mellitus; Dose-Response Relationship, Drug; Dyslipidemias; Female; Gene Frequency; Genetic Predisposition to Disease; Genotype; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Models, Genetic; Muscular Diseases; Myalgia; Obesity; Organic Anion Transporters; Polymorphism, Single Nucleotide; Simvastatin; Smoking | 2015 |
Combining citrulline with atorvastatin preserves glucose homeostasis in a murine model of diet-induced obesity.
Topics: AMP-Activated Protein Kinases; Animals; Atorvastatin; Cell Line, Tumor; Citrulline; Diabetes Mellitus, Type 2; Diet; Dietary Fats; Dietary Sucrose; Disease Models, Animal; Drug Therapy, Combination; Glucose; Homeostasis; Humans; Lipid Metabolism; Liver; Male; Mice, Inbred C57BL; Obesity; Sterol Regulatory Element Binding Protein 1 | 2015 |
Atorvastatin Plus Metformin Confer Additive Benefits on Subjects with Dyslipidemia and Overweight/Obese via Reducing ROCK2 Concentration.
Topics: Adult; Atorvastatin; Cross-Sectional Studies; Drug Therapy, Combination; Dyslipidemias; Female; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypoglycemic Agents; Male; Metformin; Middle Aged; Obesity; Overweight; rho-Associated Kinases; Treatment Outcome | 2016 |
Circulating MicroRNA-122 Is Associated With the Risk of New-Onset Metabolic Syndrome and Type 2 Diabetes.
Topics: Adult; Aged; Animals; Antagomirs; Atorvastatin; Blotting, Northern; Carrier Proteins; Complement Factor H; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycoproteins; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Incidence; Insulin Resistance; Lipid Metabolism; Lipoproteins, VLDL; Male; Mass Spectrometry; Metabolic Syndrome; Mice; MicroRNAs; Middle Aged; Multivariate Analysis; Obesity; Oligonucleotides; Prevalence; Prospective Studies; Real-Time Polymerase Chain Reaction; Reverse Transcriptase Polymerase Chain Reaction; Serum Albumin; Serum Albumin, Human | 2017 |
Microbiome and metabolome modifying effects of several cardiovascular disease interventions in apo-E
Topics: Acetates; Animals; Apolipoproteins E; Atherosclerosis; Atorvastatin; beta-Glucans; Butyrates; Cardiovascular Diseases; Carnitine; Cholesterol; Cholesterol, Dietary; Diet, High-Fat; Dietary Supplements; Feces; Gastrointestinal Microbiome; Hemiterpenes; Limosilactobacillus reuteri; Male; Metabolome; Mice; Obesity; Pentanoic Acids; Probiotics | 2017 |
Anti-inflammatory effect of atorvastatin ameliorates insulin resistance in monosodium glutamate-treated obese mice.
Topics: Adipose Tissue, White; Animals; Anti-Inflammatory Agents, Non-Steroidal; Atorvastatin; Blood Glucose; Cytokines; Enzyme-Linked Immunosorbent Assay; Glucose Transporter Type 4; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; I-kappa B Kinase; Immunohistochemistry; Insulin Resistance; Lipids; Male; Mice; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; RNA; Sodium Glutamate | 2010 |
Atorvastatin improves insulin sensitivity in mice with obesity induced by monosodium glutamate.
Topics: Adipose Tissue; Administration, Oral; Animals; Atorvastatin; Blood Glucose; Blotting, Western; Disease Models, Animal; Female; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Insulin; Insulin Resistance; Lipid Metabolism; Mice; Mice, Inbred ICR; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction; Signal Transduction; Sodium Glutamate | 2010 |
Targeting cholesterol at different levels in the mevalonate pathway protects fatty liver against ischemia-reperfusion injury.
Topics: Animals; Anticholesteremic Agents; Atorvastatin; Cholesterol, Dietary; Choline; Choline Deficiency; Disease Models, Animal; Disease Susceptibility; Enzyme Inhibitors; Farnesyl-Diphosphate Farnesyltransferase; Fatty Liver; Glutathione; Heptanoic Acids; Lipotropic Agents; Liver; Male; Mevalonic Acid; Mice; Mice, Inbred C57BL; Mitochondria; Obesity; Pyrroles; Quinuclidines; Reperfusion Injury | 2011 |
Suppression of inflammatory response and endothelial nitric oxide synthase downregulation in hyperlipidaemic C57BL/6J mice by eugenosedin-A.
Topics: Animals; Anti-Inflammatory Agents; Aorta; Atorvastatin; Dietary Fats; Down-Regulation; Endothelium, Vascular; Female; Heptanoic Acids; Hyperlipidemias; Inflammation; Interferon-gamma; Liver; Mice; Mice, Inbred C57BL; Mitogen-Activated Protein Kinases; Nitric Oxide; Nitric Oxide Synthase Type III; Obesity; Piperazines; Pyrroles; Random Allocation; RNA, Messenger; Tumor Necrosis Factor-alpha | 2011 |
Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
Topics: Administration, Oral; Animals; Atorvastatin; Cell Adhesion Molecules; Cytokines; Cytoprotection; Disease Models, Animal; Down-Regulation; Drug Administration Schedule; Enzyme Activation; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Liver; Male; Mice; Mice, Obese; NF-kappa B; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; RNA, Messenger; Thromboxane B2; Time Factors; Toll-Like Receptor 4 | 2012 |
Comparative study between atorvastatin and losartan on high fat diet-induced type 2 diabetes mellitus in rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Atorvastatin; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diet, High-Fat; Drug Therapy, Combination; Heptanoic Acids; Hypercholesterolemia; Hyperglycemia; Hypoglycemic Agents; Hypolipidemic Agents; Insulin Resistance; Losartan; Male; Obesity; Pioglitazone; Pyrroles; Random Allocation; Rats; Rats, Sprague-Dawley; Thiazolidinediones; Tumor Necrosis Factor-alpha | 2013 |
Enhancing organ pool by statins: is this the future?
Topics: Animals; Atorvastatin; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; Toll-Like Receptor 4 | 2012 |
Adipokines: a novel link between adiposity and carotid plaque vulnerability.
Topics: Adiposity; Aged; Anticholesteremic Agents; Apelin; Atorvastatin; Body Mass Index; Cholesterol, LDL; Cytokines; Female; Heptanoic Acids; Humans; Image Interpretation, Computer-Assisted; Intercellular Signaling Peptides and Proteins; Male; Middle Aged; Nicotinamide Phosphoribosyltransferase; Obesity; Plaque, Atherosclerotic; Predictive Value of Tests; Prospective Studies; Pyrroles; Risk Factors; Ultrasonography, Doppler, Color | 2012 |
[Atorvastatin and oxidative stress in coronary heart disease with obesity].
Topics: Adult; Aged; Antioxidants; Atorvastatin; Case-Control Studies; Coronary Disease; Dyslipidemias; Electrocardiography, Ambulatory; Electron Spin Resonance Spectroscopy; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lipid Peroxidation; Lipids; Middle Aged; Obesity; Oxidative Stress; Pyrroles | 2012 |
Impact of OATP1B1, MDR1, and CYP3A4 expression in liver and intestine on interpatient pharmacokinetic variability of atorvastatin in obese subjects.
Topics: Adult; Atorvastatin; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 1; Body Mass Index; Cytochrome P-450 CYP3A; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Intestinal Mucosa; Liver; Liver-Specific Organic Anion Transporter 1; Male; Middle Aged; Obesity; Organic Anion Transporters; Pyrroles | 2013 |
The effects of atorvastatin treatment on the fibrinolytic system in dyslipidemic patients.
Topics: Adult; Aged; Atorvastatin; Cholesterol; Diet, Fat-Restricted; Drug Administration Schedule; Female; Fibrinolysis; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Male; Middle Aged; Obesity; Plasminogen Activator Inhibitor 1; Pyrroles; Risk Factors; Smoking; Tissue Plasminogen Activator; Triglycerides | 2004 |
Potential role of angiotensin-converting enzyme inhibitors and statins on early podocyte damage in a model of type 2 diabetes mellitus, obesity, and mild hypertension.
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Atorvastatin; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Disease Models, Animal; Glomerulosclerosis, Focal Segmental; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertension; Immunoenzyme Techniques; Kidney; Kidney Glomerulus; Linear Models; Microscopy, Electron; Obesity; Pyrroles; Quinapril; Rats; Rats, Zucker; Staining and Labeling; Tetrahydroisoquinolines | 2005 |
Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control.
Topics: 3T3 Cells; Adipocytes; Animals; Atorvastatin; Biological Transport; Blood Glucose; Cell Differentiation; Cellular Senescence; Diabetes Mellitus, Type 2; Female; Gene Expression Regulation; Glucose Transporter Type 4; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Mice; Middle Aged; Obesity; Pyrroles; Reverse Transcriptase Polymerase Chain Reaction | 2006 |
Diabetes and residual risk of coronary heart disease.
Topics: Anticholesteremic Agents; Atorvastatin; Coronary Disease; Diabetes Complications; Diabetes Mellitus; Heptanoic Acids; Humans; Insulin Resistance; Obesity; Pyrroles; Risk Factors; Simvastatin | 2007 |
[The 2006 American Heart Association selection of the "top ten advances in heart disease and stroke research"].
Topics: Abnormalities, Drug-Induced; Adolescent; Adult; American Heart Association; Anti-Inflammatory Agents; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Brain Ischemia; Child; Coronary Disease; Heart Diseases; Heart Valve Prosthesis; Heart-Assist Devices; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Ischemic Attack, Transient; Middle Aged; Myocardial Infarction; Myocardial Revascularization; Obesity; Peptidyl-Dipeptidase A; Process Assessment, Health Care; Pyrroles; Stroke; Tissue Engineering; United States | 2007 |
Metabolic syndrome with early aortic atherosclerosis in a child.
Topics: Aorta, Abdominal; Aortic Diseases; Atherosclerosis; Atorvastatin; Child; Cholesterol; Cholesterol, HDL; Fish Oils; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemia, Familial Combined; Magnetic Resonance Imaging; Male; Metabolic Syndrome; Obesity; Pyrroles; Treatment Outcome; Triglycerides | 2006 |
Anti-inflammatory effects of combined treatment with acetyl salicylic acid and atorvastatin in haemodialysis patients affected by Normal Weight Obese syndrome.
Topics: Adult; Aged; Anti-Inflammatory Agents, Non-Steroidal; Anticholesteremic Agents; Aspirin; Atorvastatin; Body Fat Distribution; Body Mass Index; Body Weight; C-Reactive Protein; Cardiovascular Diseases; Cholesterol, HDL; Drug Therapy, Combination; Female; Heptanoic Acids; Humans; Inflammation; Kidney Failure, Chronic; Lipid Metabolism; Male; Middle Aged; Nutrition Assessment; Obesity; Prealbumin; Pyrroles; Renal Dialysis; Serum Albumin; Syndrome | 2008 |
Statins, leptin and regulatory T cells.
Topics: Animals; Atorvastatin; Heptanoic Acids; Humans; Leptin; Lymphocyte Activation; Neoplasms; Obesity; Pyrroles; Risk Factors; T-Lymphocytes, Regulatory; Thinness | 2008 |